Bellicum Pharmaceuticals Reports Positive Clinical Results

Shares of Bellicum Pharmaceuticals Inc. were near unchanged Thursday morning after the Texas-based biopharmaceutical firm reported that a recently-conducted clinical study to treat blood cancers showed positive results.

The study evaluated immune reconstitution, safety and anti-viral response in patients undergoing T cell-depleted, haploidentical hematopoietic stem cell transplant (haplo-HSCT), followed by administration of donor T cells that were engineered with CaspaCIDe.

Among the study highlights, the company noted that all 12 patients in the study showed more rapid immune reconstitution and reduced infections, compared with results in T cell-depleted, (haplo-HSCT) procedures. In addition, four cases of graft-versus-host disease (GvHD) were reported, and all were resolved with no recurrence following the administration of rimiducid.

BLCM shares were up 0.1% in recent trade, moving just below the midpoint of the 52-week range of $18.20 to $33.63.